Androgenetic Alopecia Clinical Trial
Official title:
A Prospective Double Blind, Placebo Controlled Study to Assess the Efficacy of Platelet-Rich Plasma on the Treatment of Androgenetic Alopecia
The purpose of this study is to determine the efficacy of treatment with Platelet-rich plasma on Androgenetic alopecia (compared with placebo), between six months and baseline.
Androgenetic alopecia (AGA) is a non-scarring patterned alopecia, multifactorial and a
genetic determined skin condition. This pathology is one of the most common forms of
progressive hair loss. It's an increasingly frequent complaint of dermatology clinic patients
and has a high impact psychologically.
The onset of AGA is gradual and when this pathology progresses, the anagen phase shortens and
the telogen phase remains constant. As a result, more hairs are in the telogen phase, and the
patient may notice an increase in hair shedding. This area varies from patient to patient and
is usually most marked at the vertex in men while women with androgenetic alopecia generally
lose hair diffusely over the crown. The incidence and prevalence of AGA increases with age.
Topical minoxidil and oral finasteride are the gold standard therapies for AGA and the only
two drugs currently that have US Food and Drug Administration (FDA)-approved indications for
the treatment of androgenetic alopecia. Minoxidil and finasteride are known to be effective
medical treatments in AGA, especially during the initial grades.
PRP is a plasma concentrate reaped from the patient's whole blood that comprises
predominantly platelets. Numerous growth factors (GFs) are present within platelet α
granules. Some of the most important of these include platelet-derived growth factor (PDGF),
transforming growth factor-beta (TGF-β), vascular endothelial growth factor (VEGF), epidermal
growth factor (EGF), and insulin-like growth factor (IGF). This GFs stimulate cell
proliferation and differentiation.
PRP was identified as having a beneficial effect on bone grafting with applications in oral
and maxillofacial surgery, orthopedic and cardiac surgery. More recently, increasing interest
is seen in the application of PRP in dermatology, for example, tissue regeneration, wound
healing such and fat grafting. It has also been shown to promote hair survival and growth,
both in vitro and in vivo.
The production of autologous PRP involves extraction of a specific volume of the patient's
whole blood, which is then placed in an automated centrifuge to separate the layers of whole
blood by their specific weight into 3 separate layers: (1) platelet-poor plasma, (2)
platelet-rich plasma and (3) red blood cells.
The patients were divided into two groups (A and B): group A received treatment with PRP on
the right half-head and the placebo on the left half-head, whereas group B received treatment
with PRP on the left half-head and the placebo on the right half-head.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02591355 -
Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment
|
N/A | |
Withdrawn |
NCT03852992 -
Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia
|
Phase 2 | |
Recruiting |
NCT06239207 -
Efficacy and Safety of Exosomes Versus Platelet Rich Plasma in Patients of Androgenetic Alopecia
|
Phase 2 | |
Completed |
NCT04945226 -
A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001
|
Phase 1/Phase 2 | |
Completed |
NCT01548066 -
The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss
|
Phase 2 | |
Completed |
NCT01437163 -
Treatment of Androgenetic Alopecia in Males and Females
|
N/A | |
Completed |
NCT01226459 -
Clinical Trial in Females for Female Pattern Hair Loss
|
Phase 3 | |
Recruiting |
NCT06118866 -
A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia
|
Phase 2 | |
Completed |
NCT06149221 -
Penetration-enhanced Direct DBD Non-thermal Plasma for Hair Loss
|
N/A | |
Withdrawn |
NCT04882969 -
Thulium Laser and KeraFactor for the Treatment of Androgenetic Alopecia
|
N/A | |
Completed |
NCT01231607 -
Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia
|
Phase 3 | |
Completed |
NCT04446429 -
Anti-Androgen Treatment for COVID-19
|
N/A | |
Completed |
NCT02729415 -
Point-of-Care Adipose-derived Cells for Hair Growth
|
N/A | |
Completed |
NCT02279823 -
A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia
|
Phase 2 | |
Not yet recruiting |
NCT01227031 -
Pharmacogenomic Study of Androgenetic Alopecia
|
N/A | |
Completed |
NCT00981461 -
Treatment of Androgenetic Alopecia in Females, 9 Beam
|
N/A | |
Completed |
NCT01451021 -
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss
|
Phase 2 | |
Completed |
NCT00151515 -
A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss
|
Phase 3 | |
Completed |
NCT03694067 -
Androgenetic Alopecia and the JAK-STAT Pathway
|
||
Completed |
NCT03689452 -
The Effect of Platelet Rich Plasma on Non-scarring Alopecia
|
N/A |